Y-Intercept (HK)’s Fate Therapeutics FATE Stock Holding History

Y-Intercept (HK)’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$108K	Buy	45,573 +800	+2%	+$2.07K	﹤0.01%	1508
2026 Q2	$121K	Buy	+44,773	New	+$82.9K	﹤0.01%	1600
2025 Q1	–	Sell	-35,360	Closed	-$58.3K	–	1322
2024 Q4	$58.3K	Buy	+35,360	New	+$89.1K	﹤0.01%	1116
2024 Q3	–	Sell	-17,053	Closed	-$55.9K	–	1472
2024 Q2	$55.9K	Buy	+17,053	New	+$74.7K	﹤0.01%	1296
2023 Q4	–	Sell	-95,698	Closed	-$203K	–	1360
2023 Q3	$203K	Buy	95,698 +63,116	+194%	+$209K	0.02%	910
2023 Q2	$155K	Buy	+32,582	New	+$180K	0.02%	978
2021 Q4	–	Sell	-6,376	Closed	-$378K	–	670
2021 Q3	$378K	Buy	6,376 +1,248	+24%	+$97.9K	0.07%	410
2021 Q2	$445K	Buy	+5,128	New	+$413K	0.11%	293

Other funds holding FATE

Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Parametrica Management Wanchai, Hong Kong $142M AUM 113.92% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Parcion Private Wealth Bellevue, Washington $1.85B AUM 22.28% 1-Year Est. Return

Northern Lights Advisors Seattle, Washington $192M AUM 14.28% 1-Year Est. Return

Owl Creek Wealth Partners Denver, Colorado $355M AUM

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

Y-Intercept (HK)'s FATE Position: Q3 2026 in Review

Y-Intercept (HK) increased its Fate Therapeutics (FATE) stake by 1.8% in Q3 2026, buying an estimated $2.07K and bringing the position to 45,573 shares worth $108K. The position accounts for ﹤0.01% of the portfolio, ranked #1508.

Y-Intercept (HK) first reported a position in FATE in Q2 2021 and has held it in 8 quarters since. The position peaked at $445K in Q2 2021. 20 funds tracked by Wall St. Rank hold FATE as of Q3 2026.

Y-Intercept (HK) held 45,573 shares of Fate Therapeutics worth $108K as of Q3 2026.
Y-Intercept (HK) bought 800 Fate Therapeutics shares in Q3 2026, an estimated $2.07K.
Fate Therapeutics made up ﹤0.01% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1508 holding.
Y-Intercept (HK) first reported a position in Fate Therapeutics in Q2 2021 and has held it in 8 quarters since.
Y-Intercept (HK)'s Fate Therapeutics position peaked at $445K in Q2 2021.
20 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.